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ABSTRACT: Covalently modiﬁed blood proteins (e.g., serum albumin adducts) are
increasingly being viewed as potential biomarkers via which the environmental causes of
human diseases may be understood. The notion that some (perhaps many) modiﬁcations
have yet to be discovered has led to the development of untargeted adductomics methods,
which attempt to capture entire populations of adducts. One such method is ﬁxed-step
selected reaction monitoring (FS-SRM), which analyses distributions of serum albumin
adducts via shifts in the mass of a tryptic peptide [Li et al. (2011) Mol. Cell. Proteomics 10,
M110.004606]. Working on the basis that FS-SRM might be able to detect biological
variation due to environmental factors, we aimed to scale the methodology for use in an
epidemiological setting. Development of sample preparation methods led to a batch workﬂow
with increased throughput and provision for quality control. Challenges posed by technical
and biological variation were addressed in the processing and interpretation of the data. A
pilot study of 20 smokers and 20 never-smokers provided evidence of an eﬀect of smoking on
levels of putative serum albumin adducts. Diﬀerences between smokers and never-smokers were most apparent in putative
adducts with net gains in mass between 105 and 114 Da (relative to unmodiﬁed albumin). The ﬁndings suggest that our
implementation of FS-SRM could be useful for studying other environmental factors with relevance to human health.
■ INTRODUCTION
Non-enzymatic covalent modiﬁcations to macromolecules
represent a source of potential biomarkers with which to
study human health and disease.1−4 In some cases,
modiﬁcations might be causally related to biological end points
(e.g., a mutagenic lesion in DNA causing cancer).5 Alter-
natively, modiﬁcations might be found in “oﬀ-pathway”
products from which “on-pathway” events may be inferred.
This latter possibility has motivated researchers to investigate
adducts of blood proteins as potential biomarkers, particularly
in studies seeking to understand the eﬀects of environmental
factors on human populations (biomonitoring, exposome
studies). The rationale for this approach is that exogenous
chemicals, or their derivatives, should tend to react with
nucleophilic amino acid residues in the proteins.6,7 Some
exogenous chemicals possess intrinsic reactivity toward proteins
(e.g., sulfur mustard),8 while others require metabolic activation
(e.g., aﬂatoxins).2 Less direct mechanisms, in which the origin
of the reactive chemical is endogenous rather than exogenous,
may also occur.9
Hemoglobin and human serum albumin (HSA) are two
blood proteins that have been used extensively for biomonitor-
ing.10−12 HSA, for example, is ideally suited for this purpose
due to its reactivity (at Cys-34 and other nucleophilic loci),13
abundance (approximately 40 g L−1 in serum),14 and long
physiological half-life (approximately 3 weeks).15 Some adducts
of blood proteins have been known for decades, and targeted
methods for their detection have been established.2 It is only
recently, however, that “-ome” concepts have been applied to
DNA and protein adducts and that corresponding “-omics”
methods have been applied to their detection.1,6,11,16 The idea
that known adducts might exist within a wider adductome has
led to the development of untargeted adductomics methods for
the discovery of novel biomarkers. In 2011, Li et al. reported
the use of ﬁxed-step selected reaction monitoring (FS-SRM), a
triple quadrupole mass spectrometry (TQ-MS) method for
HSA adductomics.17 The authors detected modiﬁcations within
a short sequence of amino acid residues in HSA (residues 27−
41) via shifts in a sequence tag18 of the third-heaviest tryptic
peptide (“T3”). Such a shift may be characterized by the mass
of a putative “R” group17 (presumably attached to the sulfur
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atom of Cys-34) or, as below, by the net gain in molecular mass
due to the modiﬁcation (d).
Detection by TQ-MS involves the use of quadrupole mass
analysers to exclude all but the ions of interest. Under
appropriate conditions, a precursor ion gains a stable trajectory
in the ﬁrst quadrupole (Q1), and its product does likewise in
the third quadrupole (Q3). If, for T3 peptides of HSA adducts,
the product ions are always related to their precursors by a
constant loss of mass (i.e., a loss that is independent of d), then
the loss may be used as a basis on which to detect unknown
adducts (Figure 1A). Thus, for untargeted adductomics, the
conditions in Q3 are oﬀset relative to those in Q1 according to
the constant loss, and the respective conditions are covaried as
a function of d (Figure 1B). In FS-SRM, this covarying of
conditions is done in a stepwise fashion (pseudo constant
neutral loss scanning).1,16 By devoting more time to fewer
measurements (cf. conventional scanning), stepped methods
should beneﬁt from enhanced sensitivity, accuracy and
precision. These beneﬁts are gained at the expense of
resolution, meaning that the usefulness of FS-SRM comes
not from an ability to identify particular adducts, but rather
from the characterization of their distribution as a whole. If the
closeness of the stepwise measurements is balanced with the
range of masses transmitted by Q1, then the method should
detect any and all relevant HSA adducts. Li et al.17 refer to the
range of masses captured by a single measurement as a bin
(Figure 1B). We refer to the values of d at which measurements
are made as sampling points (SPs), and we use the variable dSP
to distinguish them from the d-values of adducts (dadduct). Each
SP can be described in terms of the m/z values of a precursor
ion and one or more product ions (Figure 1B).
Li et al.17 applied their methods (sample preparation and FS-
SRM; Figure 2) to analyses of archived plasma protein that had
been pooled according to subjects’ ethnicities and tobacco
smoking habits. Diﬀerences observed between pools suggested
that FS-SRM might be able to detect statistically signiﬁcant
diﬀerences between groups of individual samples that had not
been pooled. On this basis, we wished to use FS-SRM in an
epidemiological setting,19 which would necessitate the analysis
of tens to hundreds of samples per group. In implementing FS-
SRM for this purpose, the existing methods had to be modiﬁed
in order to achieve an acceptable throughput of samples. Novel
adaptations (e.g., use of solid-phase extraction for sample
cleanup) enabled faster sample preparation. Focusing on a
Figure 1. Theoretical basis of FS-SRM (e.g., detection of an N-
ethylmaleimide adduct at Cys-34 of HSA): (A) Upon collision-
induced dissociation (CID) of a triply protonated T3 peptide, a
constant fragment (singly charged b5) is lost, and a variable fragment
(doubly charged y16) is detected. A formal disconnection (dashed line)
distinguishes atoms belonging to the T3 peptide from those
contributing to the net gain in mass (d). (B) Sampling points (SPs)
are values of d at which ion intensities are measured. Each SP speciﬁes
a pair of m/z values that permit stable ion trajectories in Q1 and Q3,
respectively. The evenly spaced points on the plot relate to stable
trajectories of [M + 3H]3+ ions in Q1 and y16 ions in Q3. If “step” and
“bin” are of equivalent size, each adduct should be detected once and
only once. “d_125.1” is the SP at which we would expect to detect the
N-ethylmaleimide adduct (dadduct = 125 Da).
Figure 2. A workﬂow for HSA adductomics comprising sample
preparation, TQ-MS, and data processing. Processes are represented
by arrows (dashed gray line = initial method; solid black line = ﬁnal
method). HSA is extracted from serum or plasma and digested with
trypsin. Relevant digestion products are puriﬁed collectively (one of
two possible cleanup methods) and analyzed using TQ-MS (one of
two possible sample delivery methods). The raw data are processed
and tabulated in preparation for statistical analysis. Protein
concentration data from a separate assay, carried out in parallel, can
feed into the ﬁnal stages of data processing.
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narrower range of SPs enabled the throughput of TQ-MS to be
increased. Further adaptations (e.g., quality control) were
introduced to address challenges associated with technical
variation, which are a particular concern when the number of
samples is large. Methods were evaluated ﬁrst using synthetic
and semisynthetic standards (adducts of maleimides) and then
by testing for eﬀects of a model environmental factor (tobacco
smoking) on the levels of putative adducts detected in human
plasma (20 smokers and 20 never-smokers from the
ENVIRONAGE cohort).20 To our knowledge, this is the ﬁrst
example of FS-SRM being used to investigate associations
between environmental factors and levels of putative HSA
adducts in a quantitative fashion.
■ EXPERIMENTAL PROCEDURES
Chemicals. Synthetic peptides (T3, ALVLIAFAQYLQQCP-
FEDHVK; and isotopically labeled T3, AL[valine-13C5,
15N]-
LIAFAQYLQQCPFEDH[valine-13C5,
15N]K) were purchased from
Insight Biotechnology (Wembley, UK). N-(Naphthalen-1-yl)-
maleimide was purchased from Santa Cruz Biotechnology (Heidel-
berg, Germany). Bovine serum albumin, 5,5′-dithiobis(2-nitrobenzoic
acid) (Ellman’s reagent), N-ethylmaleimide (NEM), GSH, human
serum from male AB plasma, HSA, lyophilized citrated bovine plasma,
lyophilized citrated human plasma, propranolol hydrochloride, and
porcine trypsin (unmodiﬁed) were purchased from Sigma-Aldrich
(Dorset, UK). Solvents (HPLC-grade and LC-MS-grade) and other
general laboratory chemicals were purchased from Alfa Aesar
(Lancashire, UK), Fisher Scientiﬁc (Loughborough, UK), Oxoid
(Hampshire, UK), Sigma-Aldrich, or VWR International (Leicester-
shire, UK). All commercial substances were used without further
preparation except for LC-MS-grade solvents (degassed by water-bath
sonication) and lyophilized plasma (reconstituted with water). Water
for general purposes (18.2 MΩ cm) was obtained using an ELGA
puriﬁcation apparatus (Veolia Water Technologies, High Wycombe,
UK).
Preparation of Standards. An isotopically labeled internal
standard (S-carbamidomethylated isotopically labeled T3, “Cam-
iT3”) was prepared as described previously.21 Similar methods were
used to prepare a N-(naphthalen-1-yl)succinimid-3-yl derivative of T3
(Nns-T3) as a mixture of putative isomers. Details can be found in the
Supporting Information (SI). Both synthetic peptide adducts were
obtained as eluates from reversed-phase HPLC. Cam-iT3 was
quantiﬁed using analytical HPLC with ﬂuorescence detection as
described in the earlier report.21 NEM-modiﬁed HSA (Nes-HSA;
expected modiﬁcation: S-[N-ethylsuccinimid-3-yl]), for use in the
preparation of Nes+ plasma (i.e., “control plasma” containing Nes-
HSA; see below), was prepared by reacting partially reduced
commercial HSA with NEM in PBS (see SI). Nes+ plasma was
prepared by adding a solution of Nes-HSA (1.4 mg) in PBS (50 μL) to
commercial human plasma (5 mL). Nes− plasma (i.e., control plasma
lacking Nes-HSA) was prepared in the same way, except that
unmodiﬁed commercial HSA was added in place of Nes-HSA. Plasma
preparations were stored as 50 μL aliquots at −80 °C.
Summary of Sample Preparation Methods. HSA was prepared
from plasma using a method similar to that of Li et al.,17 but with the
diﬀerence that adducts were not enriched (see SI for full details).
Brieﬂy, most of the unwanted plasma protein was salted out with
ammonium sulfate, and low-molecular-weight solutes were exchanged
with Tris-HCl buﬀer (50 mM, pH 8.0). The resulting HSA-rich extract
had a ﬁnal volume of 550 μL (fresh plasma) or 450 μL (control
plasma; smaller volume due to lower protein content) and contained
protein recovered from the equivalent of 18 μL of plasma. An aliquot
of each extract, containing protein from the equivalent of 2.68 μL of
fresh plasma or 3.28 μL of control plasma, was subjected to further
processing. The conditions used for protein denaturation (TCEP
hydrochloride, methanol, heat) and digestion (trypsin, pressure
cycling, heat) were similar to those described by Li et al., but samples
were processed in batches rather than individually. The digestion
mixture was scaled down to ﬁt into a smaller tube (PCT MicroTube;
Pressure Biosciences, MA, USA). Up to 12 tubes could be
accommodated in the pressure cycling instrument (Barocycler
NEP2320; Pressure Biosciences/Constant Systems, Northants, UK).
Digestion products were prepared for FS-SRM in one of two ways: by
analytical-scale preparative HPLC (ASP-HPLC; see SI) or by solid-
phase extraction (SPE; see below). This “decoupled” approach
(cleanup followed by oﬄine TQ-MS) is preferred over conventional
hyphenated analysis because FS-SRM takes longer than the width of a
typical chromatographic peak.17 In the present study, ASP-HPLC was
used initially during method development, with SPE being introduced
later to increase the throughput of sample cleanup. For comparison,
both methods were used to fractionate a “mock digest” containing
Cam-iT3, Nns-T3, and the usual buﬀers and additives. Relevant eluates
were analyzed using electrospray ionization ion trap mass spectrom-
etry (see SI).
Solid-Phase Extraction. Digestion products were separated using
reversed-phase SPE on a polymeric sorbent (Strata-X, 30 mg/1 mL
tube; Phenomenex, Macclesﬁeld, UK). SPE tubes were attached to a
10-port vacuum manifold (Biotage, Uppsala, Sweden), and condition-
ing/loading/washing/elution were achieved by drawing solutions
through the sorbent under house vacuum. The sorbent was
conditioned with a solution of 0.1% (v/v) formic acid in acetonitrile
(1 mL), then equilibrated with a solution of 0.1% (v/v) formic acid in
17:3 (v:v) water:acetonitrile (2 × 1 mL). The reservoir of the SPE
tube was charged with a 0.1% (v/v) solution of formic acid in 37:1
(v:v) water:acetonitrile (600 μL), and digestion products were added
from the PCT MicroTube (see above). The MicroTube was washed
with a 1% (v/v) solution of formic acid in 1:1 (v:v) water:acetonitrile
(145 μL), and the washings were added to the SPE tube. Cam-iT3 (90
pmol) was added, and the tube was sealed with a poly-
(tetraﬂuoroethylene) cap (Supelco; Sigma-Aldrich, Dorset, UK). The
contents of the reservoir (pH ∼ 3) were mixed by inverting the tube
once. The cap was removed, and the digestion products and Cam-iT3
were loaded onto the sorbent. The sorbent was then washed with a
0.1% (v/v) solution of formic acid in 4:1 (v:v) water:acetonitrile (5 ×
1 mL). Peptides of interest were eluted with a 0.1% (v/v) solution of
formic acid in 1:3 (v:v) water:acetonitrile (2 × 500 μL) into a 2 mL
polypropylene microcentrifuge tube (Eppendorf, Stevenage, UK). The
eluate was vortexed-mixed to homogeneity and centrifuged (16,000 ×
g, 2 min). Supernatant (300 μL) was transferred to a centrifugal ﬁlter
unit (Costar Spin-X, nylon, pore size = 0.22 μm; Corning, New York,
USA) that had been prerinsed with eluent, and the unit was
centrifuged (10,000 × g, 1 min). Filtrate (250 μL) was transferred
to a glass autosampler vial with a 300 μL fused insert (Fisher Scientiﬁc,
Loughborough, UK).
FS-SRM. FS-SRM was performed using a Thermo TSQ Quantum
Access triple quadrupole mass spectrometer (Thermo Fisher Scientiﬁc,
Hemel Hempstead, UK) operated in SRM mode. Three major
modiﬁcations were made to the method of Li et al. (see SI for the full
method). First, the chip-based system used for sample delivery was
replaced with a Dionex Ultimate 3000 liquid chromatograph and a
Nanospray Flex ion source (both from Thermo Fisher Scientiﬁc).
Second, only 32 of the 77 SPs were used (71.1 Da ≤ dSP ≤ 210.6 Da).
The other SPs were omitted as a compromise between mass-range
coverage and analytical throughput. The chosen SPs represent a
continuous range that is uninterrupted by potential artifacts (e.g., alkali
metal ion adducts), and in which some signals of interest had been
observed by Li et al.17 Additionally, truncation of the range allowed
measurements to be scheduled in a more consistent fashion (see Table
S1). Third, diﬀerent conditions were used to ﬁlter product ions in Q3
(see SI), resulting in fewer repeat measurements per 30-s “segment” of
the analysis. As in the earlier method, putative adducts were detected
via a sequence tag consisting of a triply charged precursor ion and
three doubly charged y-ions (y15, y16, and y17; standard peptide
fragment nomenclature, see SI). Starting from 32 evenly spaced values
of precursor m/z (836 to 882.5), corresponding values of product m/z
were derived using eq 1 (x = 4, 5, 6), and corresponding values of dSP
were derived using eq 2. The use of molecular weight (Mr) accounts
for the apparent averaging of m/z that occurs when multiply charged
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ions are analyzed at low resolution. The step size, ΔdSP, was always 4.5
Da (equivalent to 1.5 m/z units of precursor space), except in an
evaluation experiment where it was reduced to 0.9 Da (0.3 m/z units
of precursor space). Sample delivery was monitored via targeted
detection of the Cam-iT3 internal standard (∼20 measurements per
segment; see Figure S1 and Table S1).
= × −m z m z M bproduct / (precursor / ) 3 ( of )
2
xr
(1)
= × − + +d m z M(precursor / ) 3 ( of[T3 3H] )SP r 3 (2)
Pilot Study of Tobacco Smoke Exposure. The study included
40 mothers from the ENVIRonmental inﬂuence ON AGEing in early
life (ENVIRONAGE) birth cohort in Belgium. Questionnaires
provided information on age, education, smoking status, ethnicity,
and prepregnancy body mass index (Table 1). All procedures were
approved by the Ethical Committee of Hasselt University and East-
Limburg Hospital. The study design and procedures were described in
detail previously.20 Brieﬂy, written informed consent was obtained
from each participating mother who gave birth in the East-Limburg
Hospital in Genk, Belgium. Twenty mothers who reported smoking
during pregnancy and 20 mothers that had never smoked were
selected based on their self-reported smoking behavior. For smokers,
the median number of cigarettes per day during pregnancy was 7.25
(maximum: 40; minimum: 1; interquartile range: 4.88−10.00; see
Table S4), and the median number of pack-years was six (interquartile
range: 4.50−9.31). Peripheral blood was collected 1 day after
parturition in Vacutainer plastic whole blood tubes with spray-coated
K2EDTA (BD, Franklin Lakes, NJ, USA). Within 20 min of blood
collection, samples were centrifuged (3200 rpm, 15 min) to isolate
plasma. Plasma was collected and stored in microcentrifuge tubes
(Eppendorf) at −80 °C. To assess the reliability of self-reported
tobacco consumption, plasma cotinine concentrations (Table S4) were
measured using an enzyme-linked immunosorbent assay kit (product
ref CO096D; Calbiotech, Spring Valley, CA, USA). Smoking status
was inferred using a cutoﬀ value of 14 ng mL−1 (typical literature
cutoﬀ for serum cotinine concentrations).22
Each smoker’s sample was paired with one from a never-smoker
based on the storage time of the plasma. Twenty pairs were distributed
randomly among ﬁve batches. For 10 randomly selected pairs, the
default order of analysis (never-smoker then smoker) was reversed. To
assess among-batch variation, an aliquot of Nes+ plasma (positive
control) was analyzed at the end of every batch. Analysts were blinded
to the identities of the subjects’ samples during sample preparation and
TQ-MS. The ﬁve batches of subjects’ samples were processed
consecutively. To assess within-batch variation, a sixth batch consisting
of nine aliquots of Nes+ plasma was also included. All 54 analyses were
then replicated using diﬀerent aliquots of the same plasma samples.
For the second round of analyses, the only change was in the order of
the batches (i.e., the order of samples within batches was the same).
The complete schedule of analyses is depicted in Figure S3.
Quantity and Quality of Extracted Protein. The concentration
of protein in each plasma extract was determined using the
bicinchoninic acid (BCA) assay (Pierce/Thermo Fisher Scientiﬁc,
Paisley, UK; manufacturer’s protocol with minor modiﬁcations).
Undiluted extracts (15 μL) were analyzed in triplicate on 96-well
microplates (Greiner Bio One, Gloucester, UK), and each plate also
included standards (commercial HSA in Tris-HCl buﬀer; ﬁve
concentrations in duplicate) and quality controls (pooled extracts of
Nes+ plasma). The experimental design described above was
transferred to the microplate format, so that extracts in the same
batch, or from diﬀerent aliquots of the same plasma, were always
analyzed on the same microplate. BCA working reagent (185 μL) was
added to each well, and the microplate was incubated at 37 °C for 30
min. After 10 min at ambient temperature, a microplate spectropho-
tometer (Biotek Instruments, Bedfordshire, UK) was used to measure
the absorbances (λ = 595 nm). A calibration curve was established
from the standards’ concentrations and mean absorbances (linear
regression analysis) and was used to estimate the concentration of
protein in each extract. The absolute mass of protein in each extract
was calculated by multiplying the estimated concentration by the
volume. The quality of the protein was inferred from a set of three
example extracts (one each of smoker’s plasma, never-smoker’s plasma
and Nes+ plasma), which were analyzed using SDS-PAGE (see SI).
Processing of FS-SRM Data. Initial processing of raw data was
done using the methods of Li et al. with minor modiﬁcations.
MATLAB code (see Acknowledgments) was used to calculate the
apparent amounts of adducts in each eluate and to exclude any result
coming from a missing or incomplete sequence tag (MATLAB,
version 8.2.0.701, The MathWorks, Natick, MA, USA; see SI). The
additional validation step described by Li et al. was used for a parallel
analysis of aggregated data (see Results and Discussion), but not to
exclude any individual data from statistical testing. Partially validated
data were processed further in R (version 3.2.4; base package).23 To
account for variation due to diﬀerent concentrations of HSA in the
plasma extracts, adduct amounts were normalized using results from
the BCA assay (see SI). Null responses (missing or incomplete
sequence tags) were imputed using random estimates of baseline noise
(see SI). Stability of the MS conditions was inferred from SRM of the
internal standard (ﬁrst measurement of every cycle; see Table S1).
Unstable segments were identiﬁed by comparing stability metrics
(segment-wise means and coeﬃcients of variation) to threshold values
(Table S5). Any data acquired in unstable segments were excluded at
this stage (exclusion rate for ENVIRONAGE data: 4.3%). Best
estimates of response variables for the ENVIRONAGE samples were
derived from pairs of full technical replicates by averaging if possible. If
a result was missing or appeared to be a false negative (null response
with nonzero counterpart), its counterpart was taken as the best
estimate. This was done using an R script based on Table S6, and the
resulting table of best estimates was the primary data set used for
statistical testing.
Statistical Methods. All statistical tests were carried out using R
(version 3.2.4).23 The signiﬁcance level was p = 0.05 unless stated
otherwise. The dependence of responses on concentration variables
was assessed using linear regression analysis. A two-tailed independent
samples t-test was used to test the hypothesis that the smokers and
never-smokers diﬀered in the masses of protein recovered from their
plasma. The Pearson correlation coeﬃcient (r) was used to compare
masses of protein recovered in technical replicates. The similarity
between pairs of adduct distributions from FS-SRM (spectral
similarity;24 one coeﬃcient per pair, 32 SPs per comparison) was
quantiﬁed as the Spearman rank correlation coeﬃcient (ρ). Spear-
man’s ρ was also used to test for agreement between technical
replicates (one coeﬃcient per SP, ≤40 subjects per comparison). The
Wilcoxon rank-sum test (one test per SP, 40 subjects per comparison)
was used to test for associations between smoking status and levels of
Table 1. Characteristics of Participants Included in the
Tobacco Smoke Studya
Value
Characteristic Never-Smokers Smokers
N 20 20
Ethnicity
European-
Caucasian
20 (100) 19 (95)
Non-European 1 (5)
Age (years) 28.15 (5.12) 25.90 (5.30)
Body mass index (kg m−2) 24.29 (4.78) 24.33 (5.88)
Education
Low 3 (15) 5 (25)
Medium 6 (30) 9 (45)
High 11 (55) 6 (30)
Number of cigarettes per day 0 10 (8.69)
aCounts and percentages for categorical variables; means and standard
deviations for continuous variables.
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putative HSA adducts. Principal component analysis was used to assess
the degree of correlation among the 32 sets of responses. Five
principal components explained 99% of the variation in the data set.
To account for making multiple comparisons while also taking the
degree of correlation into consideration,25 a corrected signiﬁcance
level of p = 0.05/5 = 0.01 was used.
■ RESULTS AND DISCUSSION
Method Development. In the present study, we adapted
the FS-SRM workﬂow described previously by Li et al.17
(Figure 2). For the steps leading to tryptic digestion of HSA,
our only major modiﬁcation was to omit the adduct enrichment
procedure (removal of mercapto-HSA using covalent chroma-
tography). In an earlier study, Funk et al.26 showed that such a
procedure can facilitate high-level adduct enrichment, but
noted that better results were obtained when the protein
starting material had been isolated from freshly collected
plasma. When we attempted enrichment of a model adduct
spiked into commercial serum (method similar to the one
described by Li et al.;17 see SI), only a modest proportion of
the albumin was removed (mean ± s.d. = 39.5 ± 1.2%; four
replicates). Being more similar to Funk and co-workers’ results
for archived plasma protein, this result pointed to a sample-
dependent eﬀect that would have been diﬃcult to control for in
the present study. A secondary consideration was the
throughput of sample preparation, which was enhanced by
omitting the enrichment procedure (see SI).
SDS-PAGE of three example extracts (see SI and Figure S7)
indicated that HSA was always the major component and that
the ratio of HSA to the major impurity (probably transferrin14)
did not vary appreciably. From these results, we inferred
uniformity of relative HSA concentration (fraction, w/w, of
total protein) across all samples. This inference was supported
by evidence from the literature.27 In an extract consisting of
only HSA and transferrin, for example, the relative HSA
concentration should vary only between 92% and 96%
(assumption: no respective enrichment of either protein). We
considered whether it was necessary to quantify the extracted
protein prior to digestion. Quantiﬁcation is advantageous
because it allows variation in the protein concentration
(physiological and/or technical in origin) to be corrected for
by dilution. Such corrections allow the amount of an adduct to
be calculated as a fraction (w/w) of total protein. An alternative
approach would be to dilute all extracts to the same ﬁxed
volume and allow the protein concentration to vary freely.
Diﬀerent amounts of protein would be digested, and the results
of FS-SRM would relate to absolute concentrations instead of
fractions of total protein. In the present work, we explored both
possibilities: the volume was ﬁxed, and the protein concen-
tration was measured but not adjusted (see below). Results for
standards and quality controls indicated that the BCA assay
used to measure protein content was accurate, precise, and
stable (Figure S8 and Table S10).
For tryptic digestion, the method of Li et al.17 was adapted so
that samples could be processed in parallel rather than
individually. For cleanup of the digestion products, an ASP-
HPLC method was implemented initially,17,28 but was later
replaced by SPE (parallel cleanup of up to 10 samples, no
possibility of carry-over, and throughput at least twice that of
ASP-HPLC). To ensure that the range of adducts puriﬁed by
SPE was at least as wide as that of ASP-HPLC, a comparison
was made using two standards (Cam-iT3 and Nns-T3). Mass
spectrometric analyses indicated that both methods could elute
Cam-iT3 and Nns-T3 completely in a single, appropriately
sized volume of eluate (Figure S9).
Evaluation of FS-SRM. The capabilities of FS-SRM were
explored using Nes+ controls, which were mixtures of normal
human material (plasma or serum) and NEM-treated HSA
(Nes-HSA). Analysis of Nes+ plasma produced a distinctive
distribution of responses (Figure 3A). The response at one of
the SPs (d_125.1) was consistent with the presence of NEM-
modiﬁed Cys-34 (calculated d = 125 Da). The other responses
were attributed tentatively to components of normal plasma.
Analysis of Nes− plasma (no NEM treatment) conﬁrmed that
Nes-HSA was responsible for the majority of the response at
d_125.1, but not for any of the other prominent responses
(Figure 3B). Analysis of bovine plasma conﬁrmed that none of
the prominent responses were due to methods, reagents, or
some general property of plasma (Figure 3C). Since Nes-HSA
is a special case (dadduct = dSP), cases where dadduct was oﬀset
relative to dSP were also investigated. To do this, a Nes
+ serum
extract was analyzed using SPs that were closer together (ΔdSP
= 0.9 Da). From the results (Figure 4), it was possible to
simulate the eﬀect of varying dadduct on the response at dSP. This
conﬁrmed that ΔdSP = 4.5 Da was an appropriate spacing, but it
also revealed that the magnitude of the response declined as the
oﬀset increased. The results in Figure 4 also highlight how
diﬀerent adducts with similar masses could potentially be
detected at the same SP. The responsiveness of FS-SRM was
Figure 3. Distributions of putative HSA adducts (mean responses)
observed in diﬀerent plasma preparations: (A) human plasma spiked
with Nes-HSA; (B) human plasma without Nes-HSA; (C) bovine
plasma. “L” indicates the estimated detection limit. “d_125.1” is the SP
at which detection of Nes-HSA was expected. Error bars represent s.d.
for at least three technical replicates. Where only two replicates were
available, the individual data are plotted.
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investigated further by varying absolute and relative amounts of
Nes-HSA. Dilution series were prepared from an extract of
Nes+ serum (diluent: buﬀer or solution of Nes− protein), and
FS-SRM was performed as usual. In one experiment, the
relative amount of Nes-HSA was ﬁxed at 1.0% (w/w), and the
amount of total protein was varied. The dependence of the
d_125.1 response on the amount of total protein was positive
and linear (Figure 5A), and a similar trend was observed at
some of the other SPs (Figure S10). The observed
proportionality became important when investigating human
population samples in which the amount of protein was subject
to biological variation (see below). In a diﬀerent experiment,
the amount of total protein was ﬁxed, and the relative amount
of Nes-HSA was varied. The dependence of the d_125.1
response on the relative amount of Nes-HSA showed clear
evidence of linearity above ∼0.2% (w/w), but below this, the
responsiveness appeared dampened (Figure 5B). Nevertheless,
Nes-HSA was frequently still detectable in relative amounts as
low as 0.04% (w/w), and, if suspected false negatives were
discounted, the response was still positively associated with the
relative amount of Nes-HSA. The trend observed in Figure 5B
for d_125.1 was not apparent at any other SPs because the
concentration of total HSA (and therefore of other adducts)
was constant (Figure S11).
Throughput Analysis. Method development reduced the
time required for sample preparation from 85 to 22 min
(average time per sample excluding protein quantiﬁcation).
Omitting the adduct enrichment step also eliminated an
overnight incubation. Reducing the number of SPs from 77 to
32 increased the throughput of TQ-MS by an estimated 44%.
Pilot Study of Tobacco Smoke Exposure. Results for the
ENVIRONAGE subjects revealed substantial variation in the
recovery of protein (mean ± s.d. = 611 ± 138 μg). Amounts of
protein recovered from diﬀerent aliquots of the same plasma
were, however, well-correlated (r = 0.90, p = 7.53 × 10−15;
Figure S12), suggesting that much of the observed variation was
biological rather than technical. The amount of protein
recovered from self-reported smokers (mean ± s.d. = 667 ±
135 μg) was higher than that from never-smokers (mean ± s.d.
= 554 ± 120 μg), and the diﬀerence was statistically signiﬁcant
(p = 0.00794). In other populations, investigators have
observed either the opposite relationship29 or no signiﬁcant
diﬀerence.30 One possible explanation for our observations
would be a modulation of the eﬀect of smoking by pregnancy,
although the ﬁndings of other recent work are generally
inconsistent with this idea.31 To simplify interpretation of the
FS-SRM results, it was decided that statistical analyses should
focus on variation that could not be formally explained by
diﬀerences in protein concentration. Thus, an attempt was
made to correct for these diﬀerences using simple normal-
ization (eq S1), for which the compositional analysis (see
above) and the result in Figure 5A provided some justiﬁcation.
Normalized responses were found to be distributed among the
SPs in a reproducible fashion (e.g., response at d_107.1 tending
to be among the highest, response at d_93.6 tending to be
among the lowest). Reproducibility in this respect was
quantiﬁed by comparing the distribution of median responses
for a set of plasma aliquots with that for an identical second set.
The results indicated that the shapes of the distributions were
reproducible, irrespective of smoking status (spectral similarity
Figure 4. Eﬀect of separation (dSP − danalyte) on the responsiveness of
FS-SRM. The results indicate that if danalyte is more than half a step
(ΔdSP/2 = 2.25 Da) away from dSP, then the analyte will be detected at
a diﬀerent SP. This conﬁrms that ΔdSP = 4.5 Da is an appropriate size
of step.
Figure 5. Eﬀect of varying the amount of Nes-HSA on the response at d_125.1: (A) The relative amount of Nes-HSA with respect to total protein
was ﬁxed at 1% (w/w), and the amount of total protein was varied; (B) the amount of total protein was ﬁxed at 79 μg, and the amount of Nes-HSA
was varied. Linear regression analysis was performed using mean responses as deﬁned by the key (full replicate: digestion, cleanup, and MS; partial
replicate: MS only). The range of amounts of total protein derived from ENVIRONAGE subjects’ plasma is indicated in part A. “L” indicates the
estimated detection limit.
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for never-smokers: ρ = 0.84, p = 4.29 × 10−7; for smokers: ρ =
0.85, p = 3.19 × 10−7). Among the responses measured at a
given SP, there was substantial technical variation, and it was
likely that many responses lay outside of their respective linear
dynamic ranges. False negatives were relatively common (e.g.,
no response detected at d_111.6 in 16% of controls), so steps
were taken to minimize their inﬂuence on the results of
statistical testing (see Experimental Procedures). The occur-
rence of false negatives partly explains why responses for
diﬀerent aliquots of the same plasma were often not correlated.
Notably, however, a correlation was observed for responses at
d_107.1 (ρ = 0.56, p = 2.62 × 10−4). Results from controls
indicated that TQ-MS was a major source of technical variation
(Figure 6 and Table 2). An eﬀect of the order of analysis on the
magnitude of the response was also apparent, although
randomization should have mitigated any potential bias
conferred by this eﬀect.
The similarity between smokers’ and never-smokers’
distributions (spectral similarity, method as above: ρ = 0.94,
p < 2.2 × 10−16) suggested that at least some of the same
putative adducts were present in both groups. We tested for
associations between responses at SPs and smoking status and
found that the response at one SP (d_111.6) was signiﬁcantly
positively associated with smoking (p ≤ 0.000836; Figure 7 and
Table S11). Signiﬁcance was observed irrespective of the
method by which smoking status was determined, but only
when technical replicates were aggregated to exclude suspected
false negatives (see Experimental Procedures). The response at
another SP (d_170.1) was signiﬁcantly negatively associated
with smoking (p = 0.00513) when self-reported smoking
statuses were used, but the association was only nominally
signiﬁcant when the classiﬁcation was based on plasma cotinine
concentration (p = 0.0365). A third SP (d_107.1) was notable
because of a nominally signiﬁcant positive association of the
response with smoking (p = 0.0132, self-reported smoking
statuses) and because of the agreement between nonaggregated
technical replicates (see above).
The data set used for the above tests consisted of partially
validated responses (detection of complete sequence tags) and
imputed null responses (missing or incomplete sequence tags).
An assessment of speciﬁcity was made by comparing partially
and fully validated data sets. Full validation entailed quantitative
analysis of the sequence tags and provided additional evidence
that the responses were due to T3 peptides. For many of the
SPs, partially validated responses were frequently retained in
the fully validated data set. For d_107.1 and d_111.6, the
frequencies were 68% and 84%, respectively. A notable
exception was d_129.6, for which the frequency was only 3%.
This low frequency suggested that the dominant substance(s)
detected at d_129.6 were not T3 peptides.
Figure 6. Sources of technical variation inferred from apparent
amounts of Nes-HSA in Nes+ controls. Among-batch variation was
inferred from Nes+ controls processed at the ends of “subject blocks”
(i.e., batches of ENVIRONAGE samples). Within-batch variation was
inferred from batches consisting of solely of Nes+ controls. “Either”
indicates overlap between sets of technical replicates. Periodic
replacement of the nanoelectrospray emitter (“MS sessions”) was
considered as another possible source of technical variation (“MS
only”).
Table 2. Technical Variation among Subsets of Nes+ Controls at Selected SPsa
Coeﬃcient of variation for responses at SP
Type of Variation d_71.1 d_107.1 d_111.6 d_125.1 d_156.6 d_161.1
Among-batch 0.45 (0.45) 0.49 (0.64) 0.83 (1.10) 0.18 (0.18) 0.53 (0.53) 0.48 (0.48)
Within-batch (A) 0.68 (0.68) 0.94 (1.21) 0.48 (0.48) 0.38 (0.38) 0.38 (0.38) 0.54 (0.54)
Within-batch (B) 0.95 (0.95) 0.34 (1.23) 0.26 (0.26) 0.28 (0.28) 0.23 (0.23) 0.61 (0.61)
TQ-MS only 0.71 (0.71) 0.34 (0.59) 0.31 (0.61) 0.20 (0.20) 0.34 (0.34) 0.61 (0.71)
aEach value is a coeﬃcient of variation, calculated with exclusion of false negatives (no parentheses), or from all relevant responses (in parentheses).
The estimates of within-batch variation (A and B) come from diﬀerent batches. The values for d_125.1 relate to the data in Figure 6.
Figure 7. Distributions of p-values obtained from Wilcoxon rank-sum
tests (testing for associations between smoking status and responses at
SPs). The dashed lines indicate corrected and uncorrected signiﬁcance
levels (p = 0.01 and p = 0.05, respectively). The p-values showed a
limited dependency on the method used to determine smoking status
(self-report or cotinine assay).
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In terms of magnitude, our responses were clustered at the
lower end of the range reported by Li et al.17 The apparent
amounts of putative adducts (fractions, mol/mol, of total
protein) were between ∼5 ppm and ∼0.1% in the present study
(note, however, that the apparent amount was about one-tenth
of the actual amount; see Figure 5B) and between ∼5 ppm and
∼5% in the earlier study. In both studies there were notable
responses at d_72.1 and d_156.6 (our nomenclature). Li et
al.17 observed their highest responses at d_80.1, whereas we
observed low responses at this SP; and the opposite was true of
the responses at d_107.1. The origins of these inconsistencies
(presumably subtle diﬀerences in samples and/or methods)
remain unclear. We also found it instructive to consider the
results of others’ recent analyses using alternative meth-
ods.32−34 Assuming no eﬀects of diﬀerences in sample
preparation or analytical conditions (exception: use of reducing
agents precluding detection of S-thiolation), eight of the
features detected by alternative methods would, if present, be
detectable using FS-SRM. Notably, responses at d_107.1 are
consistent with feature A25 observed by Grigoryan et al.33 (d
equivalent to C7H6O) and/or an unidentiﬁed feature detected
by Chung et al.32 Responses at d_156.1 are consistent with a
putative tryptic transpeptidation product suggested by Chung
et al.32
Whatever their speciﬁc mechanisms of formation, the
putative adducts we observed must presumably have derived
from reactive small molecules in the blood or been formed
somehow during sample preparation. Reactive small molecules,
or their precursors, may enter the blood from a variety of
sources (pollution, drugs, endogenous sources, diet). The
detection limit of our method corresponds to a low-μM
concentration of adduct in plasma, which is similar to reported
plasma concentrations of drugs, endogenous chemicals, and
dietary chemicals, and is much greater than the plasma
concentrations of most pollutants.35 On this basis, a
pollutant-derived adduct would not be detected by our method
unless the adduct could accumulate to a level much higher than
that of the pollutant. The naphthoquinone adducts reported by
Lin et al.,36 for example, would be need to be enriched
approximately 103- or 104-fold to be detectable. On the other
hand, Waidyanatha et al.37 detected 1,4-benzoquinone adducts
at a level that, providing dadduct was close to dSP, could
potentially be detected by our method (although enrichment
would be required in order to quantify the adduct reliably). The
above inferences suggest that the putative adducts we observed
are less likely to be of pollutants than of chemicals from the
other sources, but further characterization will be needed to
conﬁrm their origins.
■ CONCLUSIONS
The FS-SRM methodology for analyzing distributions of HSA
adducts was adapted for increased throughput. Technical
aspects of the workﬂow were evaluated, and its ability to
detect biological variation in samples of human plasma was
explored. The mass coverage (69 Da ≤ d ≤ 213 Da) appeared
to be essentially uninterrupted and therefore suitable for
untargeted analysis. Responsiveness was non-uniform with
respect to d, but this did not preclude comparisons between
data sets. Accuracy and precision were best when the amount of
adduct was >0.2% (w/w) of the total HSA and when dadduct was
close to dSP. Levels of unknowns were often lower than 0.2%
(w/w), and the high technical variation encountered at these
levels (scatter, false negatives) had a negative eﬀect on
reproducibility. This was addressable to an extent using novel
data processing methods to aggregate sets of replicates. As a
model environmental factor, tobacco smoking appeared to
explain some of the variation observed in the human samples,
even when smoking-associated diﬀerences in protein concen-
tration were accounted for. The pilot study of tobacco smoke
exposure provides a proof of principle; despite being under-
powered, it demonstrates the possibility of detecting signiﬁcant
exposure-related diﬀerences in levels of putative adducts.
Hence, FS-SRM could also be useful for detecting HSA
adducts associated with exposures to other environmental
factors, providing that the adducts are present in relatively high
amounts. Knowledge of such associations will be valuable for
studying human diseases because of the mechanistic relevance
of the chemicals from which adducts derive. Since FS-SRM
does not support detailed structural characterization, comple-
mentary analytical platforms will be required to ﬁll in the
mechanistic details. This endeavor will beneﬁt from renewed
eﬀorts to enrich HSA adducts.
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